Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain.

Authors: Cedillo, Sergio¹, González-Domínguez, Almudena² almudena.gonzalez@weber.org.es, Ivanova-Markova, Yoana², López López, Rafael³, López-Tarruella Cobo, Sara⁴, Peña Pedrosa, José Alberto⁵

Source: PharmacoEconomics - Open. Nov2024, Vol. 8 Issue 6, p887-896. 10p.

Subject Terms: *Medical care, Olaparib, Germ cells, Breast cancer

Geographic Terms: Spain

Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina.

Authors: Rojas-Roque, Carlos^1,2, Silvestrini, Constanza¹, Argento, Fernando¹, Sugg, Daniela^3,4,5,6, Augustovski, Federico¹, Coelli, Jesica¹, Espinola, Natalia¹ nespinola@iecs.org.ar

Source: PharmacoEconomics - Open. Jul2024, Vol. 8 Issue 4, p585-598. 14p.

Subject Terms: *Budget, *Medical care, Olaparib, Bevacizumab, Ovarian cancer

Uncovering miRNA–mRNA Regulatory Networks Related to Olaparib Resistance and Resensitization of BRCA2 MUT Ovarian Cancer PEO1-OR Cells with the ATR/CHK1 Pathway Inhibitors.

Authors: Biegała, Łukasz^1,2 (AUTHOR) lukasz.biegala@edu.uni.lodz.pl, Kołat, Damian^3,4 (AUTHOR) damian.kolat@umed.lodz.pl, Gajek, Arkadiusz¹ (AUTHOR) arkadiusz.gajek@biol.uni.lodz.pl, Płuciennik, Elżbieta³ (AUTHOR) elzbieta.pluciennik@umed.lodz.pl, Marczak, Agnieszka¹ (AUTHOR) agnieszka.marczak@biol.uni.lodz.pl, Śliwińska, Agnieszka⁵ (AUTHOR) agnieszka.sliwinska@umed.lodz.pl, Mikula, Michał⁶ (AUTHOR) michal.mikula@nio.gov.pl, Rogalska, Aneta¹ (AUTHOR) agnieszka.sliwinska@umed.lodz.pl

Source: Cells (2073-4409). May2024, Vol. 13 Issue 10, p867. 31p.

Subject Terms: *POLY ADP ribose, *OLAPARIB, *OVARIAN cancer, *CELL cycle regulation, *GENE expression, *BRCA genes

Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer.

Authors: Mehra, Tarun¹ (AUTHOR) tarun.mehra@usz.ch, Lupatsch, Judith E.² (AUTHOR), Kössler, Thibaud³ (AUTHOR), Dedes, Konstantin⁴ (AUTHOR), Siebenhüner, Alexander Reinhard⁵ (AUTHOR), von Moos, Roger⁶ (AUTHOR), Wicki, Andreas⁷ (AUTHOR), Schwenkglenks, Matthias E.⁸ (AUTHOR)

Source: PLoS ONE. 4/4/2024, Vol. 19 Issue 4, p1-11. 11p.

Subject Terms: *PANCREATIC cancer, *OLAPARIB, *METASTASIS, *COMPANION diagnostics, *BUDGET

Geographic Terms: SWITZERLAND

Olaparib in treatment‐refractory isocitrate dehydrogenase 1 (IDH1)– and IDH2‐mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial.

Authors: Cecchini, Michael¹ (AUTHOR) michael.cecchini@yale.edu, Pilat, Mary Jo² (AUTHOR), Uboha, Nataliya³ (AUTHOR), Azad, Nilofer S.⁴ (AUTHOR), Cho, May⁵ (AUTHOR), Davis, Elizabeth J.⁶ (AUTHOR), Ahnert, Jordi Rodon⁷ (AUTHOR), Tinoco, Gabriel⁸ (AUTHOR), Shapiro, Geoffrey I.⁹ (AUTHOR), Khagi, Simon¹⁰ (AUTHOR), Powers, Benjamin¹¹ (AUTHOR), Spencer, Kristen¹² (AUTHOR), Groisberg, Roman¹³ (AUTHOR), Drappatz, Jan¹⁴ (AUTHOR), Chen, Li¹⁵ (AUTHOR), Das, Biswajit¹⁵ (AUTHOR), Bao, Xun² (AUTHOR), Li, Jing² (AUTHOR), Narayan, Azeet¹ (AUTHOR), Vu, Dennis¹ (AUTHOR)

Source: Cancer (0008543X). 2/15/2025, Vol. 131 Issue 4, p1-9. 9p.

Subject Terms: *OLAPARIB, *CHOLANGIOCARCINOMA, *PATIENT safety, *CLINICAL trials, *ISOCITRATE dehydrogenase

Company/Entity: NATIONAL Cancer Institute (U.S.)

Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.

Authors: Harter, P.^1,2,3 (AUTHOR), Marth, C.^1,4,5 (AUTHOR), Mouret-Reynier, M.-A.^6,7 (AUTHOR), Cropet, C.⁸ (AUTHOR), Lorusso, D.^9,10,11 (AUTHOR), Guerra-Alía, E.M.^12,13 (AUTHOR), Matsumoto, T.^14,15 (AUTHOR), Vergote, I.^16,17 (AUTHOR), Colombo, N.^18,19 (AUTHOR), Mäenpää, J.^20,21 (AUTHOR), Lebreton, C.^7,22 (AUTHOR), de Gregorio, N.^3,23 (AUTHOR), Mosconi, A.M.^11,24 (AUTHOR), Rubio-Pérez, M.J.^13,25 (AUTHOR), Bourgeois, H.^7,26 (AUTHOR), Fasching, P.A.^3,27 (AUTHOR), Cecere, S.C.^11,28 (AUTHOR), Hardy-Bessard, A.-C.^7,29 (AUTHOR), Denschlag, D.^3,30 (AUTHOR), de Percin, S.^7,31 (AUTHOR)

Source: Annals of Oncology. Feb2025, Vol. 36 Issue 2, p185-196. 12p.

Subject Terms: *CANCER patients, *OLAPARIB, *PROGNOSIS, *PATIENTS' attitudes, *OVARIAN cancer

Olaparib as treatment for platinum‐sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis.

Authors: Liu, Ying L.^1,2 (AUTHOR) liuy3@mskcc.org, Mathews, Cara A.³ (AUTHOR), Simpkins, Fiona⁴ (AUTHOR), Cadoo, Karen A.^1,5 (AUTHOR), Provencher, Diane⁶ (AUTHOR), McCormick, Colleen C.^7,8 (AUTHOR), ElNaggar, Adam C.⁹ (AUTHOR), Altman, Alon D.¹⁰ (AUTHOR), Gilbert, Lucy¹¹ (AUTHOR), Black, Destin¹² (AUTHOR), Kabil, Nashwa¹³ (AUTHOR), Taylor, Rosie N.¹⁴ (AUTHOR), Barnicle, Alan¹⁴ (AUTHOR), Munley, Jiefen Y.¹⁵ (AUTHOR), Aghajanian, Carol^1,2 (AUTHOR)

Source: Cancer (0008543X). 1/15/2025, Vol. 131 Issue 2, p1-12. 12p.

Subject Terms: *OLAPARIB, *BRCA genes, *OVARIAN cancer, *HOMOLOGOUS recombination, *TUMORS, *CLINICAL trials, *OVERALL survival

Development of a simple high-performance liquid chromatographyultraviolet detection method for olaparib in patients with ovarian cancer.

Authors: Takeo Yasu^1,2,3 yasutakeo-tky@umin.ac.jp, Ryosuke Nishijima¹, Risa Ikuta^3,4, Mikio Shirota^2,3, Haruko Iwase^3,5

Source: Drug Discoveries & Therapeutics. Dec2023, Vol. 17 Issue 6, p428-433. 6p.

Subject Terms: *OVARIAN cancer, *OLAPARIB, *DRUG monitoring, *CANCER patients, *ADENOSINE diphosphate, *ULTRAVIOLET radiation

Physiologically-based pharmacokinetic modeling for optimal dosage prediction of olaparib when co-administered with CYP3A4 modulators and in patients with hepatic/renal impairment.

Authors: Gao, Dongmei¹ (AUTHOR), Wang, Guopeng² (AUTHOR), Wu, Honghai³ (AUTHOR), Ren, Jiawei⁴ (AUTHOR) rjw@ncepu.edu.cn

Source: Scientific Reports. 11/18/2023, Vol. 13 Issue 1, p1-15. 15p.

Subject Terms: *CYTOCHROME P-450 CYP3A, *OLAPARIB, *PHARMACOKINETICS, *CONFIDENCE intervals

Micelle encapsulation zinc‐doped copper oxide nanocomposites reverse Olaparib resistance in ovarian cancer by disrupting homologous recombination repair.

Authors: Yi, Jingyan¹ (AUTHOR), Luo, Xin² (AUTHOR), Xing, Jinshan³ (AUTHOR), Gedanken, Aharon⁴ (AUTHOR), Lin, Xiukun⁵ (AUTHOR), Zhang, Chunxiang⁶ (AUTHOR) zhangchx999@163.com, Qiao, Gan^2,7 (AUTHOR) dqz377977905@swmu.edu.cn

Source: Bioengineering & Translational Medicine. May2023, Vol. 8 Issue 3, p1-17. 17p.

Subject Terms: *OVARIAN cancer, *OLAPARIB, *NANOCOMPOSITE materials, *CANCER cells, *ANTINEOPLASTIC agents, *COPPER oxide

Case Report of Complete Response to Olaparib in a Patient with Breast Cancer Brain Metastases.

Authors: Asazuma, Kazuki¹ (AUTHOR), Shimomura, Akihiko^1,2 (AUTHOR) akshimomura@hosp.ncgm.go.jp, Kawamura, Yukino^1,2 (AUTHOR), Taniyama, Tomoko¹ (AUTHOR), Shimizu, Chikako¹ (AUTHOR)

Source: Case Reports in Oncology. Jul2024, Vol. 17 Issue 1, p773-778. 6p. 2 Illustrations.

Subject Terms: *POLY ADP ribose, *OLAPARIB, *LOBULAR carcinoma, *CANCER patients, *PROTEIN-tyrosine kinases, *CANCER diagnosis

Clinical Response to Olaparib in a Patient With Leptomeningeal Carcinomatosis in Newly Diagnosed Breast Cancer With Germline BRCA2 Mutation.

Authors: Shah, Manali¹ (AUTHOR) manalishah095@gmail.com, Green, Jeremy² (AUTHOR), Hudacko, Rachel³ (AUTHOR), Cohen, Alice J.⁴ (AUTHOR)

Source: JCO Precision Oncology. 7/11/2024, Vol. 8, p1-5. 5p.

Subject Terms: *BREAST cancer, *OLAPARIB, *BRCA genes, *MENINGEAL cancer, *GERM cells, *CANCER patients

Stability Indicating Assay Method for the Quantitative Determination of Olaparib in Bulk and Pharmaceutical Dosage Form.

Authors: CHAUDHARY, Antima¹, TONK, Rajiv¹, DAGUR, Pankaj², DEY, Suddhasattya³, GHOSH, Manik² manik@bitmesra.ac.in

Source: Turkish Journal of Pharmaceutical Sciences. Oct2022, Vol. 19 Issue 5, p488-497. 10p.

Subject Terms: *DOSAGE forms of drugs, *OLAPARIB, *HYDROCHLOROTHIAZIDE, *POLY(ADP-ribose) polymerase, *AMMONIUM acetate, *LIQUID chromatography

Expression of MUS81 Mediates the Sensitivity of Castration-Resistant Prostate Cancer to Olaparib.

Authors: Gong, Lifeng¹ (AUTHOR), Tang, Yu¹ (AUTHOR), Jiang, Li¹ (AUTHOR), Tang, Wei¹ (AUTHOR), Luo, Shengjun¹ (AUTHOR)

Source: Journal of Immunology Research. 7/21/2022, p1-11. 11p. 7 Graphs.

Subject Terms: *CASTRATION-resistant prostate cancer, *OLAPARIB, *BENIGN prostatic hyperplasia, *DRUG toxicity, *INHIBITION of cellular proliferation

Remarkable Response to the Triplet Combination of Olaparib with Pembrolizumab and Bevacizumab in the Third-Line Treatment of an Ovarian Clear Cell Carcinoma Patient with an ARID1A Mutation: A Case Report.

Authors: Zhao, Yingchao (AUTHOR), Jiang, Yao (AUTHOR)

Source: OncoTargets & Therapy. Apr2022, Vol. 15, p323-328. 6p.

Subject Terms: *BEVACIZUMAB, *OLAPARIB, *PEMBROLIZUMAB, *NEOVASCULARIZATION inhibitors, *OVARIAN cancer, *PATIENTS' attitudes, *PERITONEAL cancer

NRG‐GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer.

Authors: Rimel, Bobbie J.¹ (AUTHOR) bobbie.rimel@cshs.org, Enserro, Danielle² (AUTHOR), Bender, David P.³ (AUTHOR), Jackson, Camille Gunderson⁴ (AUTHOR), Tan, Annie⁵ (AUTHOR), Alluri, Nitya⁶ (AUTHOR), Borowsky, Mark⁷ (AUTHOR), Moroney, John⁸ (AUTHOR), Hendrickson, Andrea Wahner⁹ (AUTHOR), Backes, Floor¹⁰ (AUTHOR), Swisher, Elizabeth¹¹ (AUTHOR), Powell, Matthew¹² (AUTHOR), MacKay, Helen¹³ (AUTHOR)

Source: Cancer (0008543X). Apr2024, Vol. 130 Issue 8, p1234-1245. 12p.

Subject Terms: *ENDOMETRIAL cancer, *OLAPARIB, *METASTASIS, *CANCER patients, *PROGRESSION-free survival

Inhibiting ADAM17 enhances the efficacy of olaparib in ovarian cancer spheroids.

Authors: Rogmans, Christoph¹ (AUTHOR), Dittrich, Jan¹ (AUTHOR), Hamm, Emily¹ (AUTHOR), Weimer, Jörg Paul¹ (AUTHOR), Holthaus, David^1,2 (AUTHOR), Arnold, Norbert¹ (AUTHOR), Flörkemeier, Inken¹ (AUTHOR), Maass, Nicolai¹ (AUTHOR), Jansen, Peer¹ (AUTHOR), Dempfle, Astrid³ (AUTHOR), Bauerschlag, Dirk O.¹ (AUTHOR), Hedemann, Nina¹ (AUTHOR) nina.hedemann@uksh.de

Source: Scientific Reports. 11/6/2024, Vol. 14 Issue 1, p1-14. 14p.

Subject Terms: *OVARIAN cancer, *CYTOTOXINS, *OLAPARIB, *CANCER treatment, *CELL survival, *POLY ADP ribose

Olaparib increases chemosensitivity by upregulating miR-125a-3p in ovarian cancer cells.

Authors: Wang, Zehua, Pu, Tao, Miao, Weiwei, Gao, Yi, Gao, Jianwen, Zhang, Xinyan

Source: Discover Oncology; 3/10/2025, Vol. 16 Issue 1, p1-15, 15p

Subject Terms: OLAPARIB, MICRORNA, POLY(ADP-ribose) polymerase, TUMOR growth, OVARIAN cancer, CELL growth, BRCA genes, CHEMOSENSITIZERS

Clinical Impact of Olaparib for Platinum-Sensitive Recurrent Ovarian Cancer.

Authors: Ishida, Hiroaki, Manrai, Megumi, Takashima, Akiko, Egashira, Hiroki, Nonaka, Mizuki, Shimada, Hideaki

Source: Diseases; Feb2025, Vol. 13 Issue 2, p51, 10p

Subject Terms: POLY ADP ribose, OVARIAN cancer, OLAPARIB, PROGRESSION-free survival, AGE groups

Combinatorial Effects of Cisplatin and PARP Inhibitor Olaparib on Survival, Intestinal Integrity, and Microbiome Modulation in Murine Model.

Authors: Matsumura, Mitsuki, Fujihara, Hisako, Maita, Kanna, Miyakawa, Moeko, Sakai, Yushi, Nakayama, Ryoko, Ito, Yumi, Hasebe, Mitsuhiko, Kawaguchi, Koji, Hamada, Yoshiki

Source: International Journal of Molecular Sciences; Feb2025, Vol. 26 Issue 3, p1191, 24p

Subject Terms: INFLAMMATORY bowel diseases, SHORT-chain fatty acids, ONE-way analysis of variance, TREATMENT effectiveness, OLAPARIB, POLY ADP ribose